The Board of Progenics Pharmaceuticals, Inc. accepted contingent resignations previously submitted by Peter J. Crowley and Michael D. Kishbauch, with an effective date of October 17, 2019, 90 days following the certification of the election results from the 2019 Annual Meeting of Shareholders, or such earlier time as the Board determines the responsibilities of the resigning directors have been sufficiently transitioned to the remaining Board members. Effective immediately, the Board has named Bradley L. Campbell as Chair of the Nominating and Corporate Governance Committee and Karen J. Ferrante as Chair of the Compensation Committee.